Recombinant Gas Vesicle Nanoparticles Surface Functionalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing recombinant gas vesicle nanoparticles (GVNPs) lack efficient techniques for genetic modification and functionalization, limiting their application in vaccine compositions and therapeutic carriers.
Innovation Solution
A method for preparing recombinant GVNPs involves culturing Halobacterium sp., removing GvpC, and fusing it with exogenous proteins like IgG-binding domains to create a recombinant protein that forms a complex with GVNPs, allowing for genetic modification and antibody loading, enabling their use as antigen-loaded vaccine compositions and therapeutic carriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional methods for preparing gas vesicle nanoparticles are used, then the basic structure can be obtained, but efficient genetic modification and functionalization techniques are lacking
Solution Approach 1:
The patent extracts and removes the GvpC protein from the gas vesicle structure, then replaces it with recombinant proteins containing exogenous antigens. This extraction approach enables functionalization of the gas vesicle surface while maintaining the core structural integrity, resolving the contradiction between obtaining basic structure and achieving efficient genetic modification.
Solution Approach 2:
The patent creates a universal platform where gas vesicles can be functionalized with various exogenous proteins and antigens through the GvpC replacement method. This multi-functional approach allows the same base structure to serve different applications in vaccines and therapeutics, improving both adaptability and manufacturing efficiency.
2Reliability
If gas vesicle nanoparticles are used as vaccine compositions, then antigen delivery can be achieved, but stability under physiological conditions must be ensured
Solution Approach 1:
The patent modifies the surface properties of gas vesicles by replacing GvpC with recombinant proteins having different biochemical characteristics. This parameter change in surface chemistry enables both enhanced stability under physiological conditions and improved functionalization capability for antigen delivery.
3Adaptability or versatility
If the outer surface protein GvpC is genetically modified to include exogenous proteins, then antigen loading capability is improved, but the complexity of the preparation process increases
Solution Approach 1:
The patent segments the gas vesicle preparation process into distinct steps: (1) formation of wild-type gas vesicles, (2) removal of GvpC protein, (3) expression and purification of recombinant proteins, (4) reconstitution of modified GvpC on gas vesicle surface. This segmentation simplifies each individual step while achieving the complex overall goal of antigen loading.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces biologically non-toxic, nano-sized GVNPs with a genetically modified outer surface protein, GvpC, which can be used as stable antigen carriers and therapeutic targets, enhancing their stability and functionality in physiological conditions.
Implementation Method 1
GVNPs, which provide buoyancy to cells by excluding water by hydrophobicity of the inner surface of the structure
Data Source
AI summary
The present disclosure relates to a recombinant gas vesicle nanoparticle, and the recombinant gas vesicle nanoparticle prepared by the method of the present disclosure is a nano-sized protein particle that it is biologically non-toxic and safe. Further, its outer surface protein, GvpC, can be recombined to include the exogenous protein to reconstitute gas vesicle nanoparticles presenting/mounting the exogenous protein on the surface, so that it can be used as various antigen-loaded vaccine compositions that are active under physiological conditions, therapeutic target-specific carriers, including a sensor for target-specific therapy.